

図 1




図 2




図 3. HEV-RNA トランスフェクションによる薬剤スクリーニング  
縦軸は OD 値、横軸は薬剤番号を示す。




図 4 : Inhibition ELISA による抗 HEV 抗体の検出




表 1 : ラミブジンによる抗原産生阻害率

クローン	HBs 抗原		HBc 抗原	
	1 回目	2 回目	1 回目	2 回目
#1	13.7	8.2	43.6	22.0
#3	5.9	ND	0.0	ND
#4	14.8	3.1	12.6	13.3
#G4	4.2	2.6	17.6	2.8

### Ⅲ. 研究成果の刊行に関する一覧表

## 研究成果の刊行に関する一覧表

## 書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
Ueda, K., Ito, E., Karayama, M., Ohsaki, E., Nakano, K., and Watanabe, S.	Kaposi's sarcoma-associated Virus governs gene expression profiles toward B cell transformation.	Magel, D. G. and Tyring, S.	Herpesviruses	In-Tech	Rijeka, Croatia	2012	pp93-104
上田啓次	HHV-8	新居志郎ら編	病原細菌・ウイルス図鑑	北海道大学出版会			編集中
高山和雄、川端健二、水口裕之	多能性幹細胞から肝細胞への分化誘導	後藤満一、大橋一夫	再生医療業書	朝倉書店	日本	2012	110-116

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Arnaud N, Dabo S, Maillard P, Budkowska A, Kalliampakou KI, Mavromara P, Garcin D, Hugon J, Gatignol A, Akazawa D, Wakita T, Meurs EF.	Hepatitis C virus controls interferon production through PKR activation.	PLoS One.	5(5)	e10575.	2010
Banaudha K, Orenstein JM, Korolnek T, St Laurent GC 3rd, Wakita T, Kumar A.	Primary hepatocyte culture supports hepatitis C virus replication: a model for infection-associated hepatocarcinogenesis.	Hepatology.	51(6)	1922-32.	2010
von dem Bussche A, Machida R, Li K, Loevinsohn G, Khander A, Wang J, Wakita T, Wands JR, Li J.	Hepatitis C virus NS2 protein triggers endoplasmic reticulum stress and suppresses its own viral replication.	J Hepatol.	53(5)	797-804.	2010
Hishiki T, Shimizu Y, Tobita R, Sugiyama K, Ogawa K, Funami K, Ohsaki Y, Fujimoto T, Takaku H, Wakita T, Baumert TF, Miyanari Y, Shimotohno K.	Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms.	J Virol.	84(22)	12048-57.	2010
Ikeda F, Dansako H, Nishimura G, Mori K, Kawai Y, Ariumi Y, Miyake Y, Takaki A, Nouse K, Iwasaki Y, Ikeda M, Kato N, Yamamoto K.	Amino acid substitutions of hepatitis C virus core protein are not associated with intracellular antiviral response to interferon- $\alpha$ in vitro	Liver Int	9	1324-1331	2010

Karakama Y; Sakamoto N; Itsui Y; Nakagawa M; Tasaka-Fujita M; Nishimura-Sakurai Y; Kakinuma S; Oooka M; Azuma S; Tsuchiya K; Onogi H; Hagiwara M; Watanabe M	Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase	Antimicrob Agents Chemother	54 (8)	3179-86	2010
Kondo Y, Ueno Y, Kobayashi K, Kakazu E, Shiina M, Inoue J, Tamai K, Wakui Y, <u>Tanaka Y</u> , Ninomiya M, Obara N, Fukushima K, Ishii M, Kobayashi T, Niitsuma H, Kon S, Shimosegawa T.	Hepatitis B virus replication could enhance regulatory T cell activity by producing soluble heat shock protein 60 from hepatocytes.	J Infect Dis.	202(2)	202-13	2010
Kushima Y, <u>Wakita T</u> , Hijikata M.	A disulfide-bonded dimer of the core protein of hepatitis C virus is important for virus-like particle production.	J Virol.	84(18)	9118-27.	2010
Masaki T, Suzuki R, Saeed M, Mori K, Matsuda M, Aizaki H, Ishii K, Maki N, Miyamura T, Matsuura Y, <u>Wakita T</u> , Suzuki T.	Production of infectious hepatitis C virus by using RNA polymerase I-mediated transcription.	J Virol.	84(11)	5824-35.	2010
Mishima K, Sakamoto N, Sekine-Osajima Y, Nakagawa M, Itsui Y, Azuma S, Kakinuma S, Kiyohashi K, Kitazume A, Tsuchiya K, Imamura M, Hiraga N, Chayama K, <u>Wakita T</u> , Watanabe M.	Cell culture and in vivo analyses of cytopathic hepatitis C virus mutants.	Virology..	405(2)	361-9	2010
<u>Moriishi, K.</u> , I. Shoji, Y. Mori, R. Suzuki, T. Suzuki, C. Kataoka, and Y. Matsuura.	Involvement of PA28gamma in the propagation of hepatitis C virus.	Hepatology	52(2)	411-420	2010.
Mori K, <u>Ikeda M</u> , Ariumi Y, Kato N.	Gene expression profile of Li23, a new human hepatoma cell line enables robust hepatitis C virus replication: Comparison with HuH-7 and other hepatic cell lines.	Hepatology Res	40	1248-1253	2010
Murayama A, Weng L, Date T, Akazawa D, Tian X, Suzuki T, Kato T, Tanaka Y, Mizokami M, <u>Wakita T</u> , Toyoda T.	RNA polymerase activity and specific RNA structure are required for efficient HCV replication in cultured cells.	PLoS Pathog.	6(4)	e1000885.	2010
Nakagawa M; Sakamoto N; Ueyama M; Mogushi K; Nagaie S; Itsui Y; Azuma S; Kakinuma S; Tanaka H; Enomoto N; Watanabe M	Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection	J Gastroenterol	45 (6)	656-65	2010

Nakamura M, Saito H, Ikeda M, Hokari R, Kato N, Hibi T, Miura S.	An antioxidant resveratrol significantly enhanced replication of hepatitis C virus.	World J. Gastroenterol.	16	184-192	2010
Nozaki A, Morimoto M, Kondo M, Oshima T, Numata K, Fujisawa S, Kaneko T, Miyajima E, Morita S, Mori K, Ikeda M, Kato N, Tanaka K.	Hydroxyurea as an inhibitor of hepatitis C virus RNA replication	Arch Virol.	155	601-605	2010
Nishimura-Sakurai Y; Sakamoto N; Mogushi K; Nagaie S; Nakagawa M; Itsui Y; Tasaka-Fujita M; Onuki-Karakama Y; Suda G; Mishima K; Yamamoto M; Ueyama M; Funaoka Y; Watanabe T; Azuma S; Sekine-Osajima Y; Kakinuma S; Tsuchiya K; Enomoto N; Tanaka H; Watanabe M	Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells	J Gastroenterol	45 (5)	523-36	2010
Sakamoto N; Tanaka Y; Nakagawa M; Yatsushashi H; Nishiguchi S; Enomoto N; Azuma S; Nishimura-Sakurai Y; Kakinuma S; Nishida N; Tokunaga K; Honda M; Ito K; Mizokami M; Watanabe M	ITPA gene variant protects against anemia induced by pegylated interferon-alpha and ribavirin therapy for Japanese patients with chronic hepatitis C	Hepato Res	40 (11)	1063-1071	2010
Suda G; Sakamoto N; Itsui Y; Nakagawa M; Tasaka-Fujita M; Funaoka Y; Watanabe T; Nitta S; Kiyohashi K; Azuma S; Kakinuma S; Tsuchiya K; Imamura M; Hiraga N; Chayama K; Watanabe M	IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones	Virology	407 (1)	80-90	2010
Tanaka T, Hasegawa Y, Saito M, Ikeda M, Kato N.	Generation of single-chain Fvs against detergent-solubilized recombinant antigens with a simple coating procedure	J. Biosci. Bioeng	110	374-376	2010
Mizui T; Yamashina S; Tanida I; Takei Y; Ueno T; Sakamoto N; Ikejima K; Kitamura T; Enomoto N; Sakai T; Kominami E; Watanabe S	Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy	J Gastroenterol	45 (2)	195-203	2010
Mishima K; Sakamoto N; Sekine-Osajima Y; Nakagawa M; Itsui Y; Azuma S; Kakinuma S; Kiyohashi K; Kitazume A; Tsuchiya K; Imamura M; Hiraga N; Chayama K; Wakita T; Watanabe M	Cell culture and in vivo analyses of cytopathic hepatitis C virus mutants	Virology	405 (2)	361-9	2010
Kim K; Kim KH; Kim HY; Cho HK; Sakamoto N; Cheong J	Curcumin inhibits hepatitis C virus replication via suppressing the Akt-SREBP-1 pathway	FEBS Lett	584 (4)	707-12	2010

Kameyama K;Nemoto Y;Kanai T;Shinohara T;Okamoto R;Tsuchiya K;Nakamura T;Sakamoto N;Totsuka T;Hibi T;Watanabe M	IL-2 is positively involved in the development of colitogenic CD4+ IL-7R alpha high memory T cells in chronic colitis	Eur J Immunol	40 (9)	2423-36	2010
Karakama Y, Sakamoto N, Itsui Y, Nakagawa M, Tasaka-Fujita M, Nishimura-Sakurai Y, Kakinuma S, Oooka M, Azuma S, Tsuchiya K, Onogi H, <u>Hagiwara M</u> , Watanabe M	Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase.	Antimicrob Agents Chemother.	54	3179-3186	2010
Kii I, Shiraishi A, Hiramatsu T, Matsushita T, Uekusa H, Yoshida S, Yamamoto M, Kudo A, Hagiwara M, and Hosoya T.	Strain-promoted double-click reaction for chemical modification of azido-biomolecules.	Org Biomol Chem.	8	4051-4055	2010
Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, Hagiwara M, Harper SJ, Woolard J, Ladomery MR, and Bates	Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms - a novel therapeutic strategy for angiogenesis.	J. Biol. Chem.	285	5532-5540	2010
Ogawa Y, Nonaka Y, Goto T, Ohnishi E, Hiramatsu T, Kii I, Yoshida M, Ikura T, Onogi H, Shibuya H, Hosoya T, Ito N, <u>Hagiwara M</u>	Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A.	Nature Commun	1:86		2010
Oshiumi H, <u>Ikeda M</u> , Matsumoto M, Watanabe A, Takeuchi O, Akira S, Kato N, Shimotohno K, Seya T.	Hepatitis C virus core protein abrogates the DDX3 function that enhances IPS-1-mediated IFN- $\beta$ induction.	PLoS One	5	e14528	2010
Podevin P, Carpentier A, Pène V, Aoudjehane L, Carrière M, Zaïdi S, Hernandez C, Calle V, Méritet JF, Scatton O, Dreux M, Cosset FL, <u>Wakita T</u> , Bartenschlager R, Demignot S, Conti F, Rosenberg AR, Calmus Y.	Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes.	Gastroenterology.	139(4)	1355-64.	2010
Shigoka M, Tsuchida A, Matsudo T, Nagakawa Y, Saito H, Suzuki Y, Aoki T, Murakami Y, Toyoda H, Kumada T, Bartenschlager R, Kato N, <u>Ikeda M</u> , Takashina T, Tanaka M, Suzuki R, Oikawa K, Takanashi M, Kuroda M.	Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development	Path. Int.	60	351-357	2010
Shirasaki T, Honda M, Mizuno H, Shimakami T, Okada H, Sakai Y, Murakami S, <u>Wakita T</u> , Kaneko S.	La protein required for internal ribosome entry site-directed translation is a potential therapeutic target for hepatitis C virus replication.	J Infect Dis.	202(1)	75-85.	2010

Takahashi H, Akazawa D, Kato T, Date T, Shirakura M, Nakamura N, Mochizuki H, Tanaka-Kaneko K, Sata T, Tanaka Y, Mizokami M, Suzuki T, <u>Wakita T.</u>	Biological properties of purified recombinant HCV particles with an epitope-tagged envelope.	Biochem Biophys Res Commun.	395(4)	565-71.	2010
Suzuki, T., Isobe, T., Kitagawa, M., and <u>Ueda, K.</u>	Kaposi's sarcoma-associated herpesvirus-encoded LANA positively affects on ubiquitylation of p53.	Biochem. Biophys. Res. Comm.	403	194-197	2010
<u>Tanaka Y,</u> Sugiyama M, Mizokami M.	Direct cytopathic effects of particular hepatitis B virus genotypes in immunosuppressive condition.	Uirusu	60(1)	79-86	2010
Tanaka, Y., Y. Mori, H. Tani, T. Abe, <u>K. Moriishi,</u> H. Kojima, T. Nagano, T. Okabe, T. Suzuki, M. Tatsumi, and Y. Matsuura.	Establishment of an indicator cell system for hepatitis C virus.	Microbiol. Immunol.	54(4)	206-220.	2010.
Tripathi, L. P., C. Kataoka, S. Taguwa, <u>K. Moriishi,</u> Y. Mori, Y. Matsuura, and K. Mizuguchi.	Network based analysis of hepatitis C virus Core and NS4B protein interactions	Mol. Biosyst.	6(12)	2539-2553	2010..
<u>Ueda, K.,</u> Ito, E., Karayama, M., Ohsaki, E., Nakano, K., Watanabe, S.	KSHV-infected PEL cell lines exhibit a distinct gene expression profile.	Biochem. Biophys. Res. Comm.	394	482-487	2010
<u>Yagi K,</u> Hayashi T.	Cutting-edge research on hepatitis C treatment and the clinical perspectives.	Yakugaku Zasshi	130(2)	141-142	2010
Ariumi Y, Kuroki M, Maki M, <u>Ikeda M,</u> Dansako H, Wakita T, Kato N.	The ESCRT System Is Required for Hepatitis C Virus Production.	PLoS ONE	6	e14517	2011
Ariumi Y, Kuroki M, Kushima Y, Osugi K, Hijikata M, Maki M, <u>Ikeda M,</u> Kato N.	Hepatitis C virus hijacks P-body and stress granule components around lipid droplets.	J Virol	85	6882-6892	2011
Arnaud N, Dabo S, Akazawa D, Fukasawa M, Shinkai-Ouchi F, Hugon J, <u>Wakita T,</u> Meurs EF.	Hepatitis C virus reveals a novel early control in acute immune response.	PLoS Pathog.	7(10)	e1002289.	2011
Debdab M, Carreaux F, Renault S, Soundararajan M, Fedorov O, Filippakopoulos P, Lozach O, Babault L, Tahtouh T, Baratte B, Ogawa Y, <u>Hagiwara M,</u> Eisenreich A, Rauch U, Knapp S, Meijer L, Bazureau JP	Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing.	J Med Chem	54(12)	4172-4186	2011



Funaoka Y;Sakamoto N;Suda G;Itsui Y;Nakagawa M;Kakinuma S;Watanabe T;Mishima K;Ueyama M;Onozuka I;Nitta S;Kitazume A;Kiyohashi K;Murakawa M;Azuma S;Tsuchiya K;Watanabe M	Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91	J Virol	85 (12)	5986-94	2011
Hikosaka K, Noritake H, Kimura W, Sultana N, Skarkar MT., Tagawa Y, Uezato T, Kobayashi Y, Wakita T, <u>Miura N.</u>	Expression of human factors CD81, claudin-1, scavenger receptor, and occludin in mouse hepatocytes does not confer susceptibility to HCV entry.	Biomed Res	32	143-150	2011
Hiramatsu N;Kurosaki M;Sakamoto N;Iwasaki M;Sakamoto M;Suzuki Y;Sugauchi F;Tamori A;Kakinuma S;Matsuura K;Izumi N	Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis	J Gastroenterol	46 (9)	1111-9	2011
Honda M, Takehana K, Sakai A, Tagata Y, Shirasaki T, Nishitani S, Muramatsu T, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shimakami T, Yi M, Lemon SM, Suzuki T, <u>Wakita T,</u> Kaneko S; Hokuriku Liver Study Group.	Malnutrition impairs interferon signaling through mTOR and FoxO pathways in patients with chronic hepatitis C.	Gastroenterol.	141(1)	128-40,140.e1-2.	2011
<u>Ikedo M,</u> Kawai Y, Mori K, Yano M, Abe K, Nishimura G, Dansako H, Ariumi Y, Wakita T, Yamamoto K, Kato N.	Anti-ulcer agent teprenone inhibits hepatitis C virus replication: potential treatment for hepatitis C.	Liver Int,	31	871-880	2011
Inamura M, Kawabata K, Takayama K, Tashiro K, Sakurai F, Katayama K, Toyoda M, Akutsu H, Miyagawa Y, Okita H, Kiyokawa N, Umezawa A, Hayakawa T, Furue MK, <u>Mizuguchi H.</u>	Efficient generation of hepatoblasts from human ES cells and iPS cells by transient overexpression of homeobox gene HEX.	Mol. Ther.	19	400-407	2011
Kadokura M;Maekawa S;Sueki R;Miura M;Komase K;Shindo H;Amemiya F;Uetake T;Inoue T;Sakamoto M;Nakagawa M;Sakamoto N;Watanabe M;Enomoto N	Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy	Hepatol Int	5 (3)	789-99	2011
Kadokura M;Maekawa S;Sueki R;Miura M;Komase K;Shindo H;Amemiya F;Uetake T;Inoue T;Sakamoto M;Nakagawa M;Sakamoto N;Watanabe M;Enomoto N	Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy	PLoS One	6 (9)	e24514	2011

Kakutani H, Takahashi A, Kondoh M, Sakihama T, Hamakubo T, <u>Yagi K.</u>	A novel screening system for claudin binder using baculoviral display.	PLoS ONE	14;6(2)	e16611	2011
Kambara, H., Tani, H., Mori, Y., Abe, T., Katoh, H., Fukuhara, T., Taguwa, S., <u>Moriishi, K.</u> , and Matsuura, Y.	Involvement of cyclophilin B in the replication of Japanese encephalitis virus.	Virology	412, (1)	211-219	2011
Kataoka N, Diem MD, Yoshida M, 4, Hatai C, Dobashi I, Dreyfuss G, <u>Hagiwara M.</u> , and Ohno M.	Specific Y14 domains mediate its nucleo-cytoplasmic shuttling and association with spliced mRNA.	Scientific Reports	doi:10	1038/srep00092	2011
Kurosaki M;Sakamoto N;Iwasaki M;Sakamoto M;Suzuki Y;Hiramatsu N;Sugauchi F;Tamori A;Nakagawa M;Izumi N	Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis	J Med Virol	83 (3)	445-52	2011
Kurosaki M;Sakamoto N;Iwasaki M;Sakamoto M;Suzuki Y;Hiramatsu N;Sugauchi F;Yatsuhashi H;Izumi N	Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis	J Gastroenterol	46 (3)	401-419	2011
Wu S, Imazeki F, Kurbanov F, Fukai K, Arai M, Kanda T, Yonemitsu Y, <u>Tanaka Y.</u> , Mizokami M, Yokosuka O.	Evolution of hepatitis B genotype C viral quasi-species during hepatitis B e antigen seroconversion.	J Hepatol,	54(1)	19-25	2011
Kawabata K., Inamura M., <u>Mizuguchi H.</u>	Efficient hepatic differentiation from human iPS cells by gene transfer.	Methods Mol. Biol.	826	115-124	2012
Kawabata K., Takayama K., Nagamoto Y., Saldon M.S., Higuchi M., <u>Mizuguchi H.</u>	Endodermal and hepatic differentiation from human embryonic stem cells and human induced pluripotent stem cells.	J. Stem Cell Res. Ther.	S10:002	2-9	2012
Kimura W, Machii M, Xue X-D, Sultana N, Hikosaka K, Sharkar MTK, Uezato T, Matsuda M, Koseki H, <u>Miura, N.</u>	Irx11 mutant mice show reduced tendon differentiation and no patterning defects in musculoskeletal system development.	Genesis	49	2-9	2011
Kurosaki M;Tanaka Y;Nishida N;Sakamoto N;Enomoto N;Honda M;Sugiyama M;Matsuura K;Sugauchi F;Asahina Y;Nakagawa M;Watanabe M;Sakamoto M;Maekawa S;Sakai A;Kaneko S;Ito K;Masaki N;Tokunaga K;Izumi N;Mizokami M	Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors	J Hepatol	54 (3)	439-48	2011

Kusano-Kitazume A; Sakamoto N; Okuno Y; Sekine-Osajima Y; Nakagawa M; Kakinuma S; Kiyohashi K; Nitta S; Murakawa M; Azuma S; Nishimura-Sakurai Y; Hagiwara M; Watanabe M	Identification of novel N-(morpholine-4-carbonyloxy) amidine compounds as potent inhibitors against hepatitis C virus replication	Antimicrob Agents Chemother	56 (3)	1315-23	2012
Mori K, Ikeda M, Ariumi Y, Dansako H, Wakita T, Kato N.	Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system.	Virus Res	157	61-70	2011
Nakamura I, Tanaka Y, Ochiai K, Moriyasu F, Mizokami M, Imawari M.	Clarification of interspousal hepatitis C virus infection in acute hepatitis C patients by molecular evolutionary analyses: Consideration on sexual and non-sexual transmission between spouses.	Hepatol Res.	41(9)	838-845	2011
Ninomiya K, Kataoka N, Hagiwara M.	Stress-responsive maturation of Clk1/4 pre-mRNAs promotes phosphorylation of SR splicing factor.	J Cell Biol.	195(1)	27-40	2011
Nishida A, Kataoka N, Takeshima Y, Yagi M, Awano, H, Ota, M, Itoh K, Hagiwara M, and Matsuo M	Chemical treatment enhances skipping of a mutated exon in the dystrophin gene.	Nature Commun	2	308	2011
Okamoto Y, Masaki T, Murayama A, Munakata T, Nomoto A, Nakamoto S, Yokosuka O, Watanabe H, Wakita T, Kato T.	Development of recombinant hepatitis C virus with NS5A from strains of genotypes 1 and 2.	Biochem Biophys Res Commun.	410(3)	404-9.	2011
Onozuka I; Kakinuma S; Kamiya A; Miyoshi M; Sakamoto N; Kiyohashi K; Watanabe T; Funaoka Y; Ueyama M; Nakagawa M; Koshikawa N; Seiki M; Nakauchi H; Watanabe M	Cholestatic liver fibrosis and toxin-induced fibrosis are exacerbated in matrix metalloproteinase-2 deficient mice	Biochem Biophys Res Commun	406 (1)	134-40	2011
Saeed M, Shiina M, Date T, Akazawa D, Watanabe N, Murayama A, Suzuki T, Watanabe H, Hiraga N, Imamura M, Chayama K, Choi Y, Krawczynski K, Liang TJ, Wakita T, Kato T.	In vivo adaptation of hepatitis C virus in chimpanzees for efficient virus production and evasion of apoptosis.	Hepatology.	54(2)	425-33.	2011
Saeed M, Suzuki R, Watanabe N, Masaki T, Tomonaga M, Muhammad A, Kato T, Matsuura Y, Watanabe H, Wakita T, Suzuki T.	Role of the endoplasmic reticulum-associated degradation (ERAD) pathway in degradation of hepatitis C virus envelope proteins and production of virus particles.	J Biol Chem.	286(43)	37264-73.	2011

Sakamoto N;Nakagawa M;Tanaka Y;Sekine-Osajima Y;Ueyama M;Kurosaki M;Nishida N;Tamori A;Yuki NS;Itsui Y;Azuma S;Kakinuma S;Hige S;Itoh Y;Tanaka E;Hiasa Y;Izumi N;Tokunaga K;Mizokami M;Watanabe M	Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b	J Med Virol	83 (5)	871-878	2011
Salim MT, Aoyama H, Sugita K, Watashi K, <u>Wakita T</u> , Hamasaki T, Okamoto M, Urata Y, Hashimoto Y, Baba M.	Potent and selective inhibition of hepatitis C virus replication by novelphenanthridinone derivatives.	Biochem Biophys Res Commun.	415(4)	714-9.	2011
Sa-nguanmoo P, <u>Tanaka Y</u> , Ratanakorn P, Sugiyama M, Murakami S, Payungporn S, Sommanustweechai A, Mizokami M, Poovorawan Y.	Cross-species transmission of gibbon and orangutan hepatitis B virus to uPA/SCID mice with human hepatocytes.	Virus Research	158(1-2)	209-15	2011
Sugiyama M, Tanaka Y, <u>Wakita T</u> , Nakanishi M, Mizokami M.	Genetic Variation of theIL-28B Promoter Affecting Gene Expression.	PLoS One.	6(10)	e26620.	2011
Taguwa, S., Kambara, H., Fujita, N., Noda, T., Yoshimori, T., Koike, K., <u>Moriishi, K.</u> , and Matsuura, Y.	Dysfunction of autophagy participates in vacuole formation and cell death in cells replicating hepatitis C virus.	J. Virol.	85 (24)	13185-13194.	2011.
Takaya D;Yamashita A;Kamijo K;Gomi J;Ito M;Maekawa S;Enomoto N;Sakamoto N;Watanabe Y;Arai R;Umeyama H;Honma T;Matsumoto T;Yokoyama S	A new method for induced fit docking (genius) and its application to virtual screening of novel HCV NS3-4A protease inhibitors	Bioorg Med Chem	19 (22)	6892-905	2011
<u>Ueda, K.</u> , Ohsaki, E., Nakano, K., and Zheng, X.	Characterization of Kaposi's sarcoma-associated virus-associated lymphomas by DNA array analysis.	Leukemia Research and Treatment		doi:10.4061/2011/7269642.	2011
Takayama K., Inamura M., Kawabata K., Katayama K., Higuchi M., Tashiro K., Nonaka A., Sakurai F., Hayakawa T., Furue M.K., <u>Mizuguchi H.</u>	Efficient generation of functional hepatocytes from human embryonic stem cells and induced pluripotent stem cells by HNF4 $\alpha$ transduction.	Mol. Ther.	20	127-137	2012
Takayama K., Inamura M., Kawabata K., Tashiro K., Katayama K., Hayakawa T., Furue M.K., <u>Mizuguchi H.</u>	Efficient and selective generation of two distinct endoderm lineages from human ES and iPS cells by differentiation stage-specific SOX17 transduction.	PLoS One	6	e21780	2011

Tanaka Y;Kurosaki M;Nishida N;Sugiyama M;Matsuura K;Sakamoto N;Enomoto N;Yatsuhashi H;Nishiguchi S;Hino K;Hige S;Itoh Y;Tanaka E;Mochida S;Honda M;Hiasa Y;Koike A;Sugauchi F;Kaneko S;Izumi N;Tokunaga K;Mizokami M	Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C	Hum Mol Genet	20 (17)	3507-3516	2011
Takeshita S, Ichikawa T, Taura N, Miyaaki H, Matsuzaki T, Otani M, Muraoka T, Akiyama M, Miura S, Ozawa E, <u>Ikeda M</u> , Kato N, Isomoto H, Tkashima F, Nakao K.	Geranylgeranylacetone has anti-hepatitis C virus activity via activation of mTOR in humanhepatoma cells.	J Gastroenterol	47(2):	195-202	2012
Toyoda M;Kitaoka A;Machida K;Nishinakagawa T;Yada R;Kohjima M;Kato M;Kotoh K;Sakamoto N;Shiota G;Nakamuta M;Nakashima M;Enjoji M	Association between lipid accumulation and the cannabinoid system in Huh7 cells expressing HCV genes	Int J Mol Med	27 (5)	619-24	2011
Ueda Y, Mori K, Ariumi Y, <u>Ikeda M</u> , Kato N.	Plural assay systems derived from different cell lines and hepatitis C virus strains are required for the objective evaluation of anti-hepatitis C virus reagents.	Biochem. Biophys. Res. Commun.	409	663-668	2011
Ueyama M;Nakagawa M;Sakamoto N;Onozuka I;Funaoka Y;Watanabe T;Nitta S;Kiyohashi K;Kitazume A;Murakawa M;Nishimura-Sakurai Y;Sekine-Osajima Y;Itsui Y;Azuma S;Kakinuma S;Watanabe M	Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-alpha2b plus ribavirin	Antivir Ther	16 (7)	1081-1091	2011
Wakita Takaji , Tetsuro Suzuki, Matthew J. Evans, Kunitada Shimotohno, Kazuaki Chayama, Yoshiharu Matsuura, <u>Makoto Hijikata</u> , Kohji Moriishi, Tsukasa Seya, Nobuyuki Enomoto, Kazuhiko Koike, Nobuyuki Kato, Tatsuya Kanto, Hak Hotta	Will there be an HCV meeting in 2020? Summary of the 17 <sup>th</sup> International Meeting in Hepatitis C Virus and Related Viruses	Gastroenterology	141(1)	E1-E5	2011
Wang J, Singh US, Rawal RK, Sugiyama M, Yoo J, Jha AK, Scroggin M, Huang Z, Murray MG, Govindarajan R, <u>Tanaka Y</u> , Korba B, Chu CK.	Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.	Bioorg Med Chem Lett.	21(21)	6328-31	2011

Watanabe T;Sakamoto N;Nakagawa M;Kakinuma S;Itsui Y;Nishimura-Sakurai Y;Ueyama M;Funaoka Y;Kitazume A;Nitta S;Kiyohashi K;Murakawa M;Azuma S;Tsuchiya K;Oooka S;Watanabe M	Inhibitory effect of a triterpenoid compound, with or without alpha interferon, on hepatitis C virus infection	Antimicrob Agents Chemother	55 (6)	2537-45	2011
Wen, X., Abe, T., Kukihara, H., Taguwa, S., Mori, Y., Tani, H., Kato, N., Suzuki, T., Tatsumi, M., Moriishi, K., and Matsuura Y.	Elimination of hepatitis C virus from hepatocytes by a selective activation of therapeutic molecules.	PLoS One	6 (1)	e15967	2011
Yoshida T, Kondoh M, Yagi K.	Promising targets for anti-hepatitis C virus agents.	Curr Med Chem.	18(8)	1239-1244	2011
Yoshida T, Kondoh M, Ojima M, Mizuguchi H, Yamagishi Y, Sakamoto N, Yagi K.	Adenovirus vector-mediated assay system for hepatitis C virus replication.	Nucleic Acids Res	39(10)	e 64	2011
Yoshida T., Takayama K., Kondoh M., Sakurai F., Tani H., Sakamoto N., Matsuura Y., Mizuguchi H., Yagi K.	Use of human hepatocyte-like cells derived from induced pluripotent stem cells as a model for hepatocytes in hepatitis C virus infection.	Biochem. Biophys. Res. Commun.	416	119-124	2011
Yamamoto M;Sakamoto N;Nakamura T;Itsui Y;Nakagawa M;Nishimura-Sakurai Y;Kakinuma S;Azuma S;Tsuchiya K;Kato T;Wakita T;Watanabe M	Studies on virus kinetics using infectious fluorescence-tagged hepatitis C virus cell culture	Hepato Res	41 (3)	258-269	2011
Yamamoto M, Aizaki H, Fukasawa M, Teraoka T, Miyamura T, Wakita T, Suzuki T.	Structural requirements of virion-associated cholesterol for infectivity, buoyant density and apolipoprotein association of hepatitis C virus.	J Gen Virol.	92(Pt 9)	2082-7.	2011
Yamamoto M, Sakamoto N, Nakamura T, Itsui Y, Nakagawa M, Nishimura-Sakurai Y, Kakinuma S, Azuma S, Tsuchiya K, Kato T, Wakita T, Watanabe M.	Studies on virus kinetics using infectious fluorescence-tagged hepatitis C virus cell culture.	Hepato Res	41	258-269	2011
Yoshida T;Takayama K;Kondoh M;Sakurai F;Tani H;Sakamoto N;Matsuura Y;Mizuguchi H;Yagi K	Use of human hepatocyte-like cells derived from induced pluripotent stem cells as a model for hepatocytes in hepatitis C virus infection	Biochem Biophys Res Commun	416 (1-2)	119-24	2011
Yoshida T;Kondoh M;Ojima M;Mizuguchi H;Yamagishi Y;Sakamoto N;Yagi K	Adenovirus vector-mediated assay system for hepatitis C virus replication	Nucleic Acids Res	39 (10)	e64	2011

Yoshida T, Takayama K, Kondoh M, Sakurai F, Tani H, Sakamoto N, Matsuura Y, Mizuguchi H, Yagi K.	Use of human hepatocyte-like cells derived from induced pluripotent stem cells as a model for hepatocytes in hepatitis C virus infection.	Biochem Biophys Res Commun.	416(1-2)	119-124	2011
Zheng X;Tsuchiya K;Okamoto R;Iwasaki M;Kano Y;Sakamoto N;Nakamura T;Watanabe M	Suppression of hath1 gene expression directly regulated by hes1 via notch signaling is associated with goblet cell depletion in ulcerative colitis	Inflamm Bowel Dis	17 (11)	2251-2260	2011
Iwasaki M;Tsuchiya K;Okamoto R;Zheng X;Kano Y;Okamoto E;Okada E;Araki A;Suzuki S;Sakamoto N;Kitagaki K;Akashi T;Eishi Y;Nakamura T;Watanabe M	Longitudinal cell formation in the entire human small intestine is correlated with the localization of Hath1 and Klf4	J Gastroenterol	46 (2)	191-202	2011
Hussein H. Aly, Kunitada Shimotohno, <u>Makoto Hijikata</u> , Tsukasa Seya	In vitro models for the analysis of HCV life cycle	Microbiol. and Immunol.	56 (1)	1-9	2012
Ando T, Imamura H, Suzuki R, Aizaki H, Watanabe T, <u>Wakita T</u> , Suzuki T.	Visualization and measurement of ATP levels in living cells replicating hepatitis C virus genome RNA.	PLoS Pathog.	8(3)	e1002561.	2012
Asahina Y;Tsuchiya K;Muraoka M;Tanaka K;Suzuki Y;Tamaki N;Hoshioka Y;Yasui Y;Katoh T;Hosokawa T;Ueda K;Nakanishi H;Itakura J;Takahashi Y;Kurosaki M;Enomoto N;Nitta S;Sakamoto N;Izumi N	Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response	Hepatology	55 (1)	20-29	2012
Cheng JC;Yeh YJ;Tseng CP;Hsu SD;Chang YL;Sakamoto N;Huang HD	Let-7b is a novel regulator of hepatitis C virus replication	Cell Mol Life Sci	69 (15)	2621-33	2012
Date, T., <u>Kato, T.</u> , Kato, J., Takahashi, H., Morikawa, K., Akazawa, D., Murayama, A., Tanaka-Kaneko, K., Sata, T., Tanaka, Y., Mizokami, M., and <u>Wakita, T.</u>	Novel cell culture-adapted genotype 2a hepatitis C virus infectious clone.	J Virol	86 (19)	10805-10820	2012
Date T, Morikawa K, Tanaka Y, Tanaka-Kaneko K, Sata T, Mizokami M, <u>Wakita T.</u>	Replication and infectivity of a novel genotype 1b hepatitis C virus clone.	Microbiol Immunol.	56(5)	308-17.	2012
Fujimoto Y, Salam KA, Furuta A, Matsuda Y, Fujita O, Tani H, Ikeda M, Kato N, Sakamoto N, Maekawa S, Enomoto N, de Voogd NJ, Nakakoshi M, Tsubuki M, Sekiguchi	Inhibition of both protease and helicase activities of hepatitis C virus NS3 by an ethyl acetate extract of marine sponge Amphimedon sp.	PLoS One	7 (11)	e48635	2012

Y, Tsuneda S, Akimitsu N, Noda N, Yamashita A, Tanaka J, <u>Moriishi K</u>					
Iikura M, Furihata T, Mizuguchi M, Nagai M, <u>Ikedo M</u> , Kato N, Tsubota A, Chiba K.	ENT1, a ribavirin transporter, plays a pivotal role in antiviral efficacy of ribavirin in a hepatitis C virus replication cell system.	Antimicrob. Agents Chemother	56(3)	1407-1413	2012
Katsurada T; Kobayashi W; Tomaru U; Baba T; Furukawa S; Ishizu A; Takeda K; Sakamoto N; Asaka M; Takeda H; Kasahara M	Decrease of peripheral and intestinal NKG2A-positive T cells in patients with ulcerative colitis	PLoS One	7 (9)	e44113	2012
Kobayashi T; Hige S; Terashita K; Nakai M; Horimoto H; Sho T; Nakanishi M; Ogawa K; Chuma M; Sakamoto N; Asaka M	Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C	J Gastroenterol	47 (11)	1228-37	2012
Kondo M, <u>Moriishi K</u> , Wada H, Noda T, Marubashi S, Wakasa K, Matsuura Y, Doki Y, Mori M, Nagano H	Upregulation of nuclear PA28gamma expression in cirrhosis and hepatocellular carcinoma.	Exp. Ther. Med.	3 (3)	379-385	2012
Kurosaki M; Hiramatsu N; Sakamoto M; Suzuki Y; Iwasaki M; Tamori A; Matsuura K; Kakinuma S; Sugauchi F; Sakamoto N; Nakagawa M; Izumi N	Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C	J Hepatol	56 (3)	602-8	2012
Kurosaki M; Hiramatsu N; Sakamoto M; Suzuki Y; Iwasaki M; Tamori A; Matsuura K; Kakinuma S; Sugauchi F; Sakamoto N; Nakagawa M; Yatsuhashi H; Izumi N	Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis	Antivir Ther	17 (1)	35-43	2012
Kusano-Kitazume A; Sakamoto N; Okuno Y; Sekine-Osajima Y; Nakagawa M; Kakinuma S; Kiyohashi K; Nitta S; Murakawa M; Azuma S; Nishimura-Sakurai Y; Hagiwara M; Watanabe M	Identification of novel N-(morpholine-4-carboxyloxy) amidine compounds as potent inhibitors against hepatitis C virus replication	Antimicrob Agents Chemother	56 (3)	1315-23	2012
Li YJ; Wu HH; Weng CH; Chen YC; Hung CC; Yang CW; Wang RY; Sakamoto N; Tian YC	Cyclophilin A and Nuclear Factor of Activated T Cells Are Essential in Cyclosporine-Mediated Suppression of Polyomavirus BK Replication	Am J Transplant	12 (9)	2348-62	2012
Matsumura, T., <u>Kato, T.</u> , Sugiyama, N., Tasaka-Fujita, M., Murayama, A., Masaki, T.,	25-hydroxyvitamin D(3) suppresses hepatitis C virus production.	Hepatology	56 (4)	1231-1239	2012



Wakita, T., and Imawari, M.					
Mori K, Ikeda M, Ariumi Y, Dansako H, Wakita T, Kato N	Development of a drug assay system with hepatitis C virus genome derived from a patient with acute hepatitis C.	Virus Genes	44(3)	374-381	2012
Moriishi K, Matsuura Y	Exploitation of lipid components by viral and host proteins for hepatitis C virus infection.	Front. Microbiol.	3	54	2012
Murayama, A., Sugiyama, N., Yoshimura, S., Ishihara-Sugano, M., Masaki, T., Kim, S., Wakita, T., Mishi, S., and Kato, T.	A Subclone of HuH-7 with Enhanced Intracellular Hepatitis C Virus Production and Evasion of Virus Related-Cell Cycle Arrest.	PLoS One	7 (12)	e52697	2012
Murayama, A., Sugiyama, N., Watashi, K., Masaki, T., Suzuki, R., Aizaki, H., Mizuochi, T., Wakita, T., and Kato, T.	Japanese reference panel of blood specimens for evaluation of hepatitis C virus RNA and core antigen quantitative assays.	J Clin Microbiol	50 (6)	1943-1949	2012
Murayama, A., Kato, T., Akazawa, D., Sugiyama, N., Date, T., Masaki, T., Nakamoto, S., Tanaka, Y., Mizokami, M., Yokosuka, O., Nomoto, A., and Wakita, T.	Production of infectious chimeric hepatitis C virus genotype 2b harboring minimal regions of JFH-1.	J Virol	86 (4)	2143-2152	2012
Nagamoto Y., Tashiro K., Takayama K., Ohashi K., Kawabata K., Sakurai F., Tachibana M., Hayakawa T., Furue MK., Mizuguchi H.	Promotion of hepatic maturation of human pluripotent stem cells in 3D co-culture using type I collagen and Swiss 3T3 cell sheets.	Biomaterials	33	4523-4534	2012
Nakagawa M; Sakamoto N; Watanabe T; Nishimura-Sakurai Y; Onozuka I; Azuma S; Kakinuma S; Nitta S; Kiyohashi K; Kusano-Kitazume A; Murakawa M; Yoshino K; Itsui Y; Tanaka Y; Mizokami M; Watanabe M; Group OLCS	Association of ITPA gene variant and serum ribavirin concentration with blood cells decline in pegylated interferon-alfa plus ribavirin therapy for chronic hepatitis C.	Hepatol Int			2012 EPub ahead of print
Nakano, K., Katano, H., Tadagaki, K., Sato, Y., Ohsaki, E., Mori, Y., Yamanishi, K., and Ueda, K.	Novel Monoclonal Antibodies for Identification of Multicentric Castleman's Disease; Kaposi's Sarcoma-Associated Herpesvirus-Encoded vMIP-I and vMIP-II.	Virology	425	95-102	2012

Nichols DB;Fournet G;Gurukumar KR;Basu A;Lee JC;Sakamoto N;Kozielski F;Musmuca I;Joseph B;Ragno R;Kaushik-Basu N	Inhibition of hepatitis C virus NS5B polymerase by S-trityl-L-cysteine derivatives	Eur J Med Chem	49	191-9	2012
Noma, S., Ohya-Shimada, W., Kanai, M., <u>Ueda, K.</u> , Nakamura, T., Funakoshi, H.	Overexpression of HGF attenuates the degeneration of Purkinje cells and Bergmann glia in a knockin mouse model of spinocerebellar ataxia type 7.	Neuroscience Res.	73	115-121	2012
Ohsaki, E. and <u>Ueda, K.</u>	Kaposi's Sarcoma-Associated Herpesvirus Genome Replication, Partition and Maintenance in the Latency.	Frontiers in Virology	3	7-19	2012
Ragheb M, Elkady A, <u>Tanaka Y</u> , Murakami S, Attia FM, Hassan AA, Hassan MF, Shedid MM, Abdel Reheem HB, Khan A, Mizokami M.	Multiple intra-familial transmission patterns of hepatitis B virus genotype D in north-eastern Egypt.	J Med Virol.	84(4)	587-95	2012
Sakurai, F., Furukawa, N., Higuchi, M., Okamoto, S., Ono, K., Yoshida, T., Kondoh, M., <u>Yagi, K.</u> , Sakamoto, N., Katayama, K., Mizuguchi, H.	Suppression of hepatitis C virus replicon by adenovirus vector-mediated expression of tough decoy RNA against miR-122a	Virus Res.	165(2)	214-218	2012
Suzuki,R., Saito,K., <u>Kato,T.</u> , Shirakura,M., Akazawa,D., Ishii,K., Aizaki,H., Kanegae,Y., Matsuura,Y., Saito,I., Wakita,T., and Suzuki,T.	I Trans-complemented hepatitis C virus particles as a versatile tool for study of virus assembly and infection.	Virology	432 (1)	29-38	2012
Weng L, Kohara M, <u>Wakita T</u> , Shimotohno K, Toyoda T.	Detergent-induced activation of the hepatitis C virus genotype 1b RNA polymerase.	Gene.	496(2)	79-87.	2012
Saito H;Ito K;Sugiyama M;Matsui T;Aoki Y;Imamura M;Murata K;Masaki N;Nomura H;Adachi H;Hige S;Enomoto N;Sakamoto N;Kurosaki M;Mizokami M;Watanabe S	Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients	Hepatol Res	42 (10)	958-965	2012
Sakamoto T, <u>Tanaka Y</u> , Watanabe T, Iijima S, Kani S, Sugiyama M, Murakami S, Matsuura K, Kusakabe A, Shinkai N, Fuminaka S, Mizokami M.	Mechanism of the dependence of hepatitis B virus genotype G on co-infection with other genotypes for viral replication.	J Viral Hepat.	in press.		2012

Sakurai F;Furukawa N;Higuchi M;Okamoto S;Ono K;Yoshida T;Kondoh M;Yagi K;Sakamoto N;Katayama K;Mizuguchi H	Suppression of hepatitis C virus replicon by adenovirus vector-mediated expression of tough decoy RNA against miR-122a	Virus Research	165 (2)	214-218	2012
Sejima H, Mori K, Ariumi Y, <u>Ikeda M</u> , Kato N.	Identification of host genes showing differential expression profiles with cell-based long-term replication of hepatitis C virus RNA.	Virus Res.	167(1)	74-85	2012
Sunbul M, Sugiyama M, Kurbanov F, Leblebicioglu H, Khan A, Elkady A, <u>Tanaka Y</u> , Mizokami M.	Specific mutations of basal core promoter are associated with chronic liver disease in hepatitis B virus subgenotype D1 prevalent in Turkey.	Microbiol Immunol.	in press.		2012
Takayama K., Inamura M., Kawabata K., Sugawara M., Kikuchi K., Higuchi M., Nagamoto Y., Watanabe H., Tashiro K., Sakurai F., Hayakawa T., <u>Furue MK.</u> , <u>Mizuguchi H.</u>	Generation of metabolically functioning hepatocytes from human pluripotent stem cells by FOXA2 and HNF1 $\alpha$ transduction.	J. Hepatol.	57	628-636	2012
Takeshita S, Ichikawa T, Taura N, Miyaaki H, Matsuzaki T, Otani M, Muraoka T, Akiyama M, Miuma S, Ozawa E, <u>Ikeda M</u> , Kato N, Isomoto H, Tkashima F, Nakao K.	Geranylgeranylacetone has anti-hepatitis C virus activity via activation of mTOR in human hepatoma cells.	J Gastroenterol	47(2):	195-202	2012
Tripathi LP, Kambara H, <u>Moriishi K</u> , Morita E, Abe T, Mori Y, Chen YA, Matsuura Y, Mizuguchi K	Proteomic Analysis of Hepatitis C Virus (HCV) Core Protein Transfection and Host Regulator PA28 $\gamma$ Knockout in HCV Pathogenesis: A Network-Based Study.	J. Proteome Res.	11(7)	3664-3679,	2012
Takeda M, <u>Ikeda M</u> , Ariumi Y, Wakita T, Kato N	Development of hepatitis C virus production reporter assay systems using two different hepatoma cell lines.	J. Gen. Virol.	93(7)	1422-1431	2012
Takeda M, <u>Ikeda M</u> , Mori K, Yano M, Ariumi Y, Dansako H, Wakita T, Kato N.	Raloxifene inhibits hepatitis C virus infection and replication.	FEBS Open Bio.	2	279-283	2012
<u>Ueda, K.</u>	For the future studies of Kaposi's sarcoma-associated herpesvirus.	Frontiers in Virology	3	1-2	2012
<u>Ueda, K.</u>	Kaposi's Sarcoma-associated Herpesvirus Induced Tumorigenesis; how viral oncogenic insults are evaded.	J. Blood and Lymph	2	3	2012

Yamashita A;Salam KA;Furuta A;Matsuda Y;Fujita O;Tani H;Fujita Y;Fujimoto Y;Ikeda M;Kato N;Sakamoto N;Maekawa S;Enomoto N;Nakakoshi M;Tsubuki M;Sekiguchi Y;Tsuneda S;Akimitsu N;Noda N;Tanaka J;Moriishi K	Inhibition of Hepatitis C Virus Replication and Viral Helicase by Ethyl Acetate Extract of the Marine Feather Star <i>Alloeocomatella polycladia</i>	Marine Drugs	10 (4)	744-761	2012
Haba S;Yamao K;Bhatia V;Mizuno N;Hara K;Hijioka S;Imaoka H;Niwa Y;Tajika M;Kondo S;Tanaka T;Shimizu Y;Yatabe Y;Hosoda W;Kawakami H;Sakamoto N	Diagnostic ability and factors affecting accuracy of endoscopic ultrasound-guided fine needle aspiration for pancreatic solid lesions: Japanese large single center experience.	J Gastroenterol			2013 Epub ahead of print
Huang JT;Tseng CP;Liao MH;Lu SC;Yeh WZ;Sakamoto N;Chen CM;Cheng JC	Hepatitis C virus replication is modulated by the interaction of non-structural protein NS5B and fatty acid synthase.	J Virol			2013 in press
Kohjima M;Enjoji M;Yoshimoto T;Yada R;Fujino T;Aoyagi Y;Fukushima N;Fukuizumi K;Harada N;Yada M;Kato M;Kotoh K;Nakashima M;Sakamoto N;Tanaka Y;Nakamura M	Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C	J Med Virol	85 (2)	250-60	2013
Kiyohashi K;Kakinuma S;Kamiya A;Sakamoto N;Nitta S;Yamanaka H;Yoshino K;Fujiki J;Murakawa M;Kusano-Kitazume A;Shimizu H;Okamoto R;Azuma S;Nakagawa M;Asahina Y;Tanimizu N;Kikuchi A;Nakauchi H;Watanabe M	Wnt5a Signaling Mediates Biliary Differentiation of Fetal Hepatic Stem/Progenitor Cells.	Hepatology			2013 in press
Nitta S;Sakamoto N;Nakagawa M;Kakinuma S;Mishima K;Kusano-Kitazume A;Kiyohashi K;Murakawa M;Nishimura-Sakurai Y;Azuma S;Tasaka-Fujita M;Asahina Y;Yoneyama M;Fujita T;Watanabe M	Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type I interferon-dependent innate immunity	Hepatology	57 (1)	46-58	2013
Rawal RK, Singh US, Chavre SN, Wang J, Sugiyama M, Hung W, Govindarajan R, Korba B, Tanaka Y, Chu CK.	2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: In vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action.	Bioorg Med Chem Lett.	23(2)	503-6	2013